Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

Immunoglobulin (IG) replacement therapy in patients with primary immunodeficiency diseases (PID) can be administered daily to every 2 weeks subcutaneously (SCIG) or every 3 or 4 weeks intravenously (IVIG). Develop a population pharmacokinetic (PK) model simulating IG exposure with Ig20Gly, a 20% SCI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2019-06, Vol.71, p.404-410
Hauptverfasser:	Dumas, Todd, Berry, N. Seth, Wolfsegger, Martin, Jolles, Stephen, McCoy, Barbara, Yel, Leman
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adolescent Adult Aged Aged, 80 and over Bioavailability Child Child, Preschool Clinical Protocols Computer Simulation Datasets Dosage Dose adjustment Drug Dosage Calculations Exposure Female Humans Ig20Gly Immunodeficiency Immunoglobulin Immunoglobulins Immunoglobulins, Intravenous - pharmacokinetics Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - drug therapy Injections, Subcutaneous Intervals Intravenous administration Male Middle Aged Modelling Pharmacokinetic modeling Pharmacokinetics Pharmacology Population Groups Predictions Primary immunodeficiencies Software Subcutaneous Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!